Diabetes, a worldwide disease;Le diabète, une maladie mondialisée

Presse Medicale

Volumn 33, Issue SPEC. ISS., 2004, Pages

  Halimi, Serge ^a   Benhamou, Pierre Yves ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; INSULIN; SULFONYLUREA DERIVATIVE;

DIABETES MELLITUS; ENVIRONMENTAL FACTOR; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; WORLD HEALTH;

EID: 3543040679     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26:917-32
2. Kluger J. The diabetes explosion. Time Magazine (September 4) 2000; disponible sur: http:/www.time.com.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
4. Diamond J. The double puzzle of diabetes. Nature 2003; 423:599-602.
5. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962; 14: 353-62.
6. Isoma B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the Metabolic Syndrome. Diabetes Care 2001; 24:683-689.
7. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
8. Velho G, Froguel P, Clement K et al. Primary pancreatic beta-cell secretory defect caused by mutations in the glucokinase in kindreds of maturity onset diabetes of the young. Lancet 1992; 340: 444-8.
9. Poitout V, Robertson RP. Secondary failure in type 2 diabetes. A convergence for glucotoxicity and lipotoxicity. Endocrinology 2002; 143:339-43.
10. UKPDS. a message of hope and a need for change. United Kingdom Prospective Diabetes Study. Watkins PJ Diabet Med 1998; 15:895-6.
11. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.
12. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type 1 diabetes - the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-403.
13. Hyppönen E, Virtanen S, Kenward MG, Knip M, Akerblom HK, Obesity increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 2000; 23: 1755-60.
14. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-8.
15. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumor immunity. Nat Rev Immunol 2003; 3: 211-22.
16. Ziegler AG, Hummel M, Schenker M et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999;48:460-8.
17. Ryan EA, Lakey JR, Rajotte RV et al. Clinical outcome and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-19.
18. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9.